FDA Determines Regulatory Review Period for LENVIMA Patent Extension

Summary

The U.S. Food and Drug Administration (FDA) has officially approved the regulatory review period for LENVIMA, a human drug product, following a submission to the U.S. Patent and Trademark Office (USPTO) for patent extension.